Obstructive Lung Disease Market Research Report By Disease Type (Asthma, Bronchitis, Copd), By Product Type (Inhalers, Nebulizers), Drug Class (Combination Drug, Lta, Ics, Saba, Laba), Route of Administration, End User- Forecast till 2032

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Route of Administration Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Obstructive lung disease Market, by Disease Type

6.1 Introduction

6.2 Asthma

6.2.1 Market Estimates & Forecast, 2022 – 2030

6.3 Bronchiectasis

6.3.1 Market Estimates & Forecast, 2022 – 2030

6.4 Bronchitis

6.4.1 Market Estimates & Forecast, 2022 – 2030

6.5 Chronic obstructive pulmonary disease (COPD)

6.5.1 Market Estimates & Forecast, 2022 – 2030

6.6 Others

Chapter 7. Global Obstructive lung disease Market, by Product Type

7.1 Introduction

7.2 Inhalers

7.2.1 Market Estimates & Forecast, 2022 – 2030

7.2.2 Drug Powder Inhalers (DPIs)

7.2.2.1 Market Estimates & Forecast, 2022 – 2030

7.2.3 Metered Dose Inhalers (MDIs),

7.2.3.1 Market Estimates & Forecast, 2022 – 2030

7.2.4 Soft Mist Inhalers (SMIs)

7.2.4.1 Market Estimates & Forecast, 2022 – 2030

7.2.5 Others

7.3 Nebulizers

7.3.1 Market Estimates & Forecast, 2022 – 2030

7.3.2 Compressor nebulizers

7.3.2.1 Market Estimates & Forecast, 2022 – 2030

7.3.3 Ultrasonic nebulizers

7.3.3.1 Market Estimates & Forecast, 2022 – 2030

7.3.4 Mesh nebulizers

7.3.4.1 Market Estimates & Forecast, 2022 – 2030

7.4 Others

Chapter 8. Global Obstructive lung disease Market, by Drug Class

8.1 Introduction

8.2 Combination drugs

8.2.1 Market Estimates & Forecast, 2022 – 2030

8.2.2 Seretide/ advair

8.2.2.1 Market Estimates & Forecast, 2022 – 2030

8.2.3 Symbicort

8.2.3.1 Market Estimates & Forecast, 2022 – 2030

8.2.4 Relvar/breo ellipta

8.2.4.1 Market Estimates & Forecast, 2022 – 2030

8.2.5 Flutiform

8.2.5.1 Market Estimates & Forecast, 2022 – 2030

8.2.6 Dulera

8.2.6.1 Market Estimates & Forecast, 2022 – 2030

8.2.7 Others

8.3 Leukotriene antagonists (LTA),

8.3.1 Market Estimates & Forecast, 2022 – 2030

8.3.2 Singulair

8.3.2.1 Market Estimates & Forecast, 2022 – 2030

8.3.3 Others

8.4 Anticholinergics

8.4.1 Market Estimates & Forecast, 2022 – 2030

8.4.2 Spiriva

8.4.2.1 Market Estimates & Forecast, 2022 – 2030

8.4.3 Others

8.5 Short acting beta agonists (SABA)

8.5.1 Market Estimates & Forecast, 2022 – 2030

8.5.2 Proair

8.5.2.1 Market Estimates & Forecast, 2022 – 2030

8.5.3 Ventolin

8.5.3.1 Market Estimates & Forecast, 2022 – 2030

8.5.4 Others

8.6 Inhaled corticosteroids (ICS)

8.6.1 Market Estimates & Forecast, 2022 – 2030

8.6.2 Qvar

8.6.2.1 Market Estimates & Forecast, 2022 – 2030

8.6.3 Pulmicort

8.6.3.1 Market Estimates & Forecast, 2022 – 2030

8.6.4 Aerospan

8.6.4.1 Market Estimates & Forecast, 2022 – 2030

8.6.5 Flovent

8.6.5.1 Market Estimates & Forecast, 2022 – 2030

8.6.6 Others

8.7 Long acting beta agonists (LABA)

8.7.1 Market Estimates & Forecast, 2022 – 2030

8.8 Others

Chapter 9. Global Obstructive lung disease Market, by Route of Administration

9.1 Introduction

9.2 Oral

9.2.1 Market Estimates & Forecast, 2022 – 2030

9.3 Inhaler

9.3.1 Market Estimates & Forecast, 2022 – 2030

9.4 Intravenous

9.4.1 Market Estimates & Forecast, 2022 – 2030

9.5 Subcutaneous

9.5.1 Market Estimates & Forecast, 2022 – 2030

9.6 Others

Chapter 10. Global Obstructive lung disease Market, by End User

10.1 Introduction

10.2 Hospitals & Diagnostic Centers

10.2.1 Market Estimates & Forecast, 2022 – 2030

10.3 Academic Institutes

10.3.1 Market Estimates & Forecast, 2022 – 2030

10.4 Pharmaceutical & Biotechnology

10.4.1 Market Estimates & Forecast, 2022 – 2030

10.5 Others

10.5.1 Market Estimates & Forecast, 2022 – 2030

Chapter. 11 Global Obstructive lung disease Market, by Region

11.1 Introduction

11.2 Americas

11.2.1 North America

11.2.1.1 U.S.

11.2.1.1 Canada

11.2.2 South America

11.3 Europe

11.3.1 Western Europe

11.3.1.1 Germany

11.3.1.2 France

11.3.1.3 Italy

11.3.1.4 Spain

11.3.1.5 U.K

11.3.1.6 Rest of Western Europe

11.3.2 Eastern Europe

11.4 Asia Pacific

11.4.1 Japan

11.4.2 China

11.4.3 India

11.4.4 Australia

11.4.5 Republic of Korea

11.4.6 Rest of Asia Pacific

11.5 The Middle East & Africa

11.5.1 United Arab Emirates

11.5.2 Saudi Arabia

11.5.3 Rest of the Middle East & Africa

Chapter 12 Company Landscape

12.1 Introduction

12.2 Market Share Analysis

12.3 Key Development & Strategies

12.3.1 Key Developments

Chapter 13 Company Profiles

13.1 GlaxoSmithKline

13.1.1 Company Overview

13.1.2 Drug Class Overview

13.1.3 Financials

13.1.4 SWOT Analysis

13.2 Novartis AG

13.2.1 Company Overview

13.2.2 Drug Class Overview

13.2.3 Financial Overview

13.2.4 Key Developments

13.2.5 SWOT Analysis

13.3 Merck & Co. Inc.

13.3.1 Company Overview

13.3.2 Drug Class Overview

13.3.3 Financial Overview

13.3.4 Key Development

13.3.5 SWOT Analysis

13.4 Abbott Laboratories

13.4.1 Company Overview

13.4.2 Drug Class/Business Segment Overview

13.4.3 Financial Overview

13.4.4 Key Development

13.4.5 SWOT Analysis

13.5 Boehringer Ingelheim

13.5.1 Company Overview

13.5.2 Drug Class Overview

13.5.3 Financial overview

13.5.4 Key Developments

13.6 AstraZeneca

13.6.1 Company Overview

13.6.2 Drug Class Overview

13.6.3 Financial Overview

13.6.4 Key Developments

13.7 Roche Holding AG

13.7.1 Overview

13.7.2 Drug Class Overview

13.7.3 Financials

13.7.4 Key Developments

13.7.5 SWOT Analysis

13.8 Teva Pharmaceutical Industries

13.8.1 Company Overview

13.8.2 Drug Class/Business Segment Overview

13.8.3 Financial Overview

13.8.4 Key Development

13.8.5 SWOT Analysis

13.9 Pfizer Inc.

13.9.1 Company Overview

13.9.2 Drug Class Overview

13.9.3 Financial overview

13.9.4 Key Developments

13.10 Others

Chapter 14 MRFR Conclusion

14.1 Key Findings

14.1.1 From CEO’s View Point

14.1.2 Unmet Needs of the Market

14.2 Key Companies to Watch

14.3 Prediction of Pharmaceutical industry

Chapter 15 Appendix

LIST OF TABLES

Table 1 Obstructive lung disease Industry Synopsis, 2022 – 2030

Table 2 Obstructive lung disease Market Estimates and Forecast, 2022 – 2030, (USD Billion)

Table 3 Obstructive lung disease Market by Region, 2022 – 2030, (USD Billion)

Table 4 Obstructive lung disease Market by Disease Type, 2022 – 2030, (USD Billion)

Table 5 Obstructive lung disease Market by Product Type, 2022 – 2030, (USD Billion)

Table 6 Obstructive lung disease Market by Drug Class, 2022 – 2030, (USD Billion)

Table 7 Obstructive lung disease Market by Route of Administration, 2022 – 2030, (USD Billion)

Table 8 Obstructive lung disease Market by End Users, 2022 – 2030, (USD Billion)

Table 9 North America Obstructive lung disease Market by Disease Type, 2022 – 2030, (USD Billion)

Table 10 North America Obstructive lung disease Market by Product Type, 2022 – 2030, (USD Billion)

Table 11 North America Obstructive lung disease Market by Drug Class, 2022 – 2030, (USD Billion)

Table 12 North America Obstructive lung disease Market by Route of Administration, 2022 – 2030, (USD Billion)

Table 13 North America Obstructive lung disease Market by End User, 2022 – 2030, (USD Billion)

Table 14 US Obstructive lung disease Market by Disease Type, 2022 – 2030, (USD Billion)

Table 15 US Obstructive lung disease Market by Product Type, 2022 – 2030, (USD Billion)

Table 16 US Obstructive lung disease Market by Drug Class, 2022 – 2030, (USD Billion)

Table 17 US Obstructive lung disease Market by Route of Administration, 2022 – 2030, (USD Billion)

Table 18 US Obstructive lung disease Market by End User, 2022 – 2030, (USD Billion)

Table 19 Canada Obstructive lung disease Market by Disease Type, 2022 – 2030, (USD Billion)

Table 20 Canada Obstructive lung disease Market by Product Type, 2022 – 2030, (USD Billion)

Table 21 Canada Obstructive lung disease Market by Drug Class, 2022 – 2030, (USD Billion)

Table 22 Canada Obstructive lung disease Market by Route of Administration, 2022 – 2030, (USD Billion)

Table 23 Canada Obstructive lung disease Market by End User, 2022 – 2030, (USD Billion)

Table 24 South America Obstructive lung disease Market by Disease Type, 2022 – 2030, (USD Billion)

Table 25 South America Obstructive lung disease Market by Product Type, 2022 – 2030, (USD Billion)

Table 26 South America Obstructive lung disease Market by Drug Class, 2022 – 2030, (USD Billion)

Table 27 South America Obstructive lung disease Market by Route of Administration, 2022 – 2030, (USD Billion)

Table 28 South America Obstructive lung disease Market by End User, 2022 – 2030, (USD Billion)

Table 29 Europe Obstructive lung disease Market by Disease Type, 2022 – 2030, (USD Billion)

Table 30 Europe Obstructive lung disease Market by Product Type, 2022 – 2030, (USD Billion)

Table 31 Europe Obstructive lung disease Market by Drug Class, 2022 – 2030, (USD Billion)

Table 32 Europe Obstructive lung disease Market by Route of Administration, 2022 – 2030, (USD Billion)

Table 33 Europe Obstructive lung disease Market by End User, 2022 – 2030, (USD Billion)

Table 34 Western Europe Obstructive lung disease Market by Disease Type, 2022 – 2030, (USD Billion)

Table 35 Western Europe Obstructive lung disease Market by Product Type, 2022 – 2030, (USD Billion)

Table 36 Western Europe Obstructive lung disease Market by Drug Class, 2022 – 2030, (USD Billion)

Table 37 Western Europe Obstructive lung disease Market by Route of Administration, 2022 – 2030, (USD Billion)

Table 38 Western Europe Obstructive lung disease Market by End User, 2022 – 2030, (USD Billion)

Table 39 Eastern Europe Obstructive lung disease Market by Disease Type, 2022 – 2030, (USD Billion)

Table 40 Eastern Europe Obstructive lung disease Market by Product Type, 2022 – 2030, (USD Billion)

Table 41 Eastern Europe Obstructive lung disease Market by Drug Class, 2022 – 2030, (USD Billion)

Table 42 Eastern Europe Obstructive lung disease Market by Route of Administration, 2022 – 2030, (USD Billion)

Table 43 Eastern Europe Obstructive lung disease Market by End User, 2022 – 2030, (USD Billion)

Table 44 Asia Pacific Obstructive lung disease Market by Disease Type, 2022 – 2030, (USD Billion)

Table 45 Asia Pacific Obstructive lung disease Market by Product Type, 2022 – 2030, (USD Billion)

Table 46 Asia Pacific Obstructive lung disease Market by Drug Class, 2022 – 2030, (USD Billion)

Table 47 Asia Pacific Obstructive lung disease Market by Route of Administration, 2022 – 2030, (USD Billion)

Table 48 Asia Pacific Obstructive lung disease Market by End User, 2022 – 2030, (USD Billion)

Table 49 The Middle East & Africa Obstructive lung disease Market by Disease Type, 2022 – 2030, (USD Billion)

Table 50 The Middle East & Africa Obstructive lung disease Market by Product Type, 2022 – 2030, (USD Billion)

Table 51 The Middle East & Africa Obstructive lung disease Market by Drug Class, 2022 – 2030, (USD Billion)

Table 52 The Middle East & Africa Obstructive lung disease Market by Route of Administration, 2022 – 2030, (USD Billion)

Table 53 The Middle East & Africa Obstructive lung disease Market by End User, 2022 – 2030, (USD Billion)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Obstructive lung disease Market

Figure 3 Segmentation Market Dynamics for Obstructive lung disease Market

Figure 4 Global Obstructive lung disease Market Share, by Disease Type 2022

Figure 5 Global Obstructive lung disease Market Share, by Product Type 2022

Figure 6 Global Obstructive lung disease Market Share, by Drug Class, 2022

Figure 8 Global Obstructive lung disease Market Share, by Route of Administration, 2022

Figure 9 Global Obstructive lung disease Market Share, by End Users, 2022

Figure 10 Global Obstructive lung disease Market Share, by Region, 2022

Figure 11 North America Obstructive lung disease Market Share, by Country, 2022

Figure 12 Europe Obstructive lung disease Market Share, by Country, 2022

Figure 13 Asia Pacific Obstructive lung disease Market Share, by Country, 2022

Figure 14 The Middle East & Africa Obstructive lung disease Market Share, by Country, 2022

Figure 15 Global Obstructive lung disease Market: Company Share Analysis, 2022 (%)

Figure 16 GlaxoSmithKline: Key Financials

Figure 17 GlaxoSmithKline: Segmental Revenue

Figure 18 GlaxoSmithKline: Geographical Revenue

Figure 19 Novartis AG: Key Financials

Figure 20 Novartis AG: Segmental Revenue

Figure 21 Novartis AG: Geographical Revenue

Figure 22 Merck & Co. Inc.: Key Financials

Figure 23 Merck & Co. Inc.: Segmental Revenue

Figure 24 Merck & Co. Inc.: Geographical Revenue

Figure 25 Abbott Laboratories: Key Financials

Figure 26 Abbott Laboratories: Segmental Revenue

Figure 27 Abbott Laboratories: Geographical Revenue

Figure 28 Boehringer Ingelheim: Key Financials

Figure 29 Boehringer Ingelheim: Segmental Revenue

Figure 30 Boehringer Ingelheim: Geographical Revenue

Figure 32 AstraZeneca: Key Financials

Figure 33 AstraZeneca: Segmental Revenue

Figure 34 AstraZeneca: Geographical Revenue

Figure 35 Roche Holding AG: Key Financials

Figure 36 Roche Holding AG: Segmental Revenue

Figure 37 Roche Holding AG: Geographical Revenue

Figure 38 Teva Pharmaceutical Industries: Key Financials

Figure 39 Teva Pharmaceutical Industries: Segmental Revenue

Figure 40 Teva Pharmaceutical Industries: Geographical Revenue

Figure 41 Pfizer Inc.: Key Financials

Figure 42 Pfizer Inc.: Segmental Revenue

Figure 43 Pfizer Inc.: Geographical Revenue